

Resource Summary Report

Generated by [NIF](#) on Jul 28, 2026

Brilliant Violet 421(TM) anti-human CD34

RRID:AB_2561358

Type: Antibody

Proper Citation

BioLegend Cat# 343610, RRID:AB_2561358

Antibody Information

URL: http://antibodyregistry.org/AB_2561358

Proper Citation: BioLegend Cat# 343610, RRID:AB_2561358

Target Antigen: CD34

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 421(TM) anti-human CD34

Description: This monoclonal targets CD34

Target Organism: human

Clone ID: Clone 561

Antibody ID: AB_2561358

Vendor: BioLegend

Catalog Number: 343610

Alternative Catalog Numbers: 343609

Record Creation Time: 20250819T214910+0000

Record Last Update: 20250820T001153+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD34.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD34.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Gao M, et al. (2025) SUCLG1 deficiency-induced histone succinylation impairs oncogene expression in acute myeloid leukemia. Cell reports, 44(8), 116147.

He S, et al. (2025) Systemic immune activity occurs during human immune system maturation. Cell, 188(25), 7291.

Sahu SU, et al. (2025) Peptide-enabled ribonucleoprotein delivery for CRISPR engineering (PERC) in primary human immune cells and hematopoietic stem cells. Nature protocols.

Derks LLM, et al. (2025) Posttransplantation clonal dynamics of hematopoietic stem cells carrying prenatal and early-life DNMT3A mutations. HemaSphere, 9(12), e70262.

Sahu S, et al. (2024) Peptide-enabled ribonucleoprotein delivery for CRISPR engineering (PERC) in primary human immune cells and hematopoietic stem cells. bioRxiv : the preprint server for biology.

Middelkamp S, et al. (2023) Comprehensive single-cell genome analysis at nucleotide resolution using the PTA Analysis Toolbox. Cell genomics, 3(9), 100389.

Martin-Rufino JD, et al. (2023) Massively parallel base editing to map variant effects in human hematopoiesis. Cell, 186(11), 2456.

Hasaart KAL, et al. (2022) Human induced pluripotent stem cells display a similar mutation burden as embryonic pluripotent cells in vivo. iScience, 25(2), 103736.

de Kanter JK, et al. (2021) Antiviral treatment causes a unique mutational signature in cancers of transplantation recipients. Cell stem cell, 28(10), 1726.

Tong J, et al. (2021) Hematopoietic Stem Cell Heterogeneity Is Linked to the Initiation and Therapeutic Response of Myeloproliferative Neoplasms. Cell stem cell, 28(3), 502.

Tong J, et al. (2021) Hematopoietic stem cell heterogeneity is linked to the initiation and therapeutic response of myeloproliferative neoplasms. Cell stem cell, 28(4), 780.

Evans WS, et al. (2020) Sitting decreases endothelial microparticles but not circulating angiogenic cells irrespective of lower leg exercises: a randomized cross-over trial. *Experimental physiology*, 105(8), 1408.

Nagpal N, et al. (2020) Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells. *Cell stem cell*, 26(6), 896.

Dinh HQ, et al. (2020) Coexpression of CD71 and CD117 Identifies an Early Unipotent Neutrophil Progenitor Population in Human Bone Marrow. *Immunity*, 53(2), 319.

Hess DA, et al. (2020) Vascular Risk Reduction in Obesity through Reduced Granulocyte Burden and Improved Angiogenic Monocyte Content following Bariatric Surgery. *Cell reports. Medicine*, 1(2), 100018.

Seo GY, et al. (2018) LIGHT-HVEM Signaling in Innate Lymphoid Cell Subsets Protects Against Enteric Bacterial Infection. *Cell host & microbe*, 24(2), 249.